MBRX - モレキュリン・バイオテック (Moleculin Biotech Inc.) モレキュリン・バイオテック

 MBRXのチャート


 MBRXの企業情報

symbol MBRx
会社名 Moleculin Biotech Inc (モレキュリン・バイオテック)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Moleculin Biotech Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin which it refers to as Annamycin an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress one involving a portfolio of small molecules which it refers to as the WP1066 Portfolio focused on the modulation of key oncogenic transcription factors involved in the progression of cancer and the WP1122 Portfolio a suite of molecules targeting the metabolic processes involved in cancer in general and glioblastoma. As of April 3 2017 it had not generated any revenue from its operations.   モレキュリン・バイオテックは米国のバイオ医薬品企業。臨床前と臨床段階において、がん治療薬の開発に焦点を当て、テキサス大学システムのMDアンダ―ソン・がんセンタ―とのライセンス契約に基づく。同社候補薬は「リボソ―ム型Annamycin」で、抵抗性急性脊髄性白血病の治療を目指す。本社はテキサス州ヒュ―ストン。   Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
本社所在地 5300 Memorial Drive Suite 950 Houston TX 77007 USA
代表者氏名
代表者役職名
電話番号 +1 713-300-5160
設立年月日 42186
市場名 NASDAQ Small Cap
ipoyear 2016年
従業員数
url www.moleculin.com
nasdaq_url https://www.nasdaq.com/symbol/mbrx
adr_tso
EBITDA EBITDA(百万ドル) -13.86700
終値(lastsale) 1.41
時価総額(marketcap) 37874710.77
時価総額 時価総額(百万ドル) 32.50241
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 20.78041
当期純利益 当期純利益(百万ドル) -13.10300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Moleculin Biotech Inc revenues was not reported. Net loss increased 88% to $7.1M. Higher net loss reflects Research and development increase from $1.2M to $5.5M (expense) Gain from expiration of warrants decrease of 55% to $1M (income) General and administrative increase of 58% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.21 to -$0.28.

 MBRXのテクニカル分析


 MBRXのニュース

   Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models  2019/12/19 12:30:00 PR Newswire
HOUSTON, Dec. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the presentation of a poster entitled,…
   Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia  2019/12/04 12:30:00 PR Newswire
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug…
   Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients  2019/11/19 12:30:00 PR Newswire
HOUSTON, Nov. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it now has preliminary data from its clinical trial…
   Moleculin Biotech (NASDAQ:MBRX) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS  2019/11/14 04:44:23 Modern Readers
Moleculin Biotech (NASDAQ:MBRX) announced its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01), Fidelity Earnings reports. NASDAQ MBRX traded up $0.03 during trading hours on Wednesday, hitting $1.07. The company’s stock had a trading volume of 163,000 shares, […]
   Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer  2019/11/13 12:30:00 Yahoo Finance
HOUSTON, Nov. 13, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it has begun preclinical testing of its drug candidate
   Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models  2019/12/19 12:30:00 PR Newswire
HOUSTON, Dec. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the presentation of a poster entitled,…
   Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia  2019/12/04 12:30:00 PR Newswire
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug…
   Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients  2019/11/19 12:30:00 PR Newswire
HOUSTON, Nov. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it now has preliminary data from its clinical trial…
   Moleculin Biotech (NASDAQ:MBRX) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS  2019/11/14 04:44:23 Modern Readers
Moleculin Biotech (NASDAQ:MBRX) announced its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01), Fidelity Earnings reports. NASDAQ MBRX traded up $0.03 during trading hours on Wednesday, hitting $1.07. The company’s stock had a trading volume of 163,000 shares, […]
   Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer  2019/11/13 12:30:00 Yahoo Finance
HOUSTON, Nov. 13, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it has begun preclinical testing of its drug candidate
   Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models  2019/12/19 12:30:00 PR Newswire
HOUSTON, Dec. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the presentation of a poster entitled,…
   Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia  2019/12/04 12:30:00 PR Newswire
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug…
   Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients  2019/11/19 12:30:00 PR Newswire
HOUSTON, Nov. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it now has preliminary data from its clinical trial…
   Moleculin Biotech (NASDAQ:MBRX) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS  2019/11/14 04:44:23 Modern Readers
Moleculin Biotech (NASDAQ:MBRX) announced its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01), Fidelity Earnings reports. NASDAQ MBRX traded up $0.03 during trading hours on Wednesday, hitting $1.07. The company’s stock had a trading volume of 163,000 shares, […]
   Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer  2019/11/13 12:30:00 Yahoo Finance
HOUSTON, Nov. 13, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it has begun preclinical testing of its drug candidate

 関連キーワード  (医薬品 米国株 モレキュリン・バイオテック MBRX Moleculin Biotech Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)